No
|
Diagnosis
|
Grade1
|
AC
|
LN
|
ER3
|
PgR3
|
HER-2
|
Bcl-2
|
E-CD
|
---|
1
|
IDC
|
G3
|
IDH
|
N1
|
0
|
0
|
0
|
80%
|
>90%
|
2
|
IDC
|
G2
|
none
|
N1
|
40%
|
0
|
0
|
80%
|
>90%
|
3
|
IDC
|
G2
|
none
|
N0
|
10%
|
2%
|
0
|
70%
|
>90%
|
4
|
IDC
|
G3
|
none
|
N0
|
90%
|
50%
|
2+ 2
|
100%
|
>90%
|
5
|
IDC
|
G2
|
DCIS
|
N0
|
90%
|
1%
|
0
|
95%
|
>90%
|
6
|
ILC
|
G2
|
LCIS
|
N0
|
0
|
0
|
0
|
30%
|
0
|
7
|
ILC
|
G1
|
none
|
N0
|
80%
|
80%
|
0
|
100%
|
0
|
8
|
ILC
|
G1
|
none
|
N1
|
50%
|
0
|
0
|
80%
|
0
|
9
|
ILC
|
G2
|
LCIS
|
N1
|
0
|
0
|
0
|
<5%
|
0
|
10
|
ILC
|
G1
|
none
|
N0
|
50%
|
70%
|
0
|
80%
|
0
|
-
1Tumors were graded using the Nottingham combined histologic grading system.
-
2No gene amplification was detected by fluorescent in situ hybridization.
-
3A complete H-score was calculated by summing the products of the percentage cells stained at a given staining intensity (0–100) and the staining intensity (0–3).
- AC, accompanying changes; DCIS, ductal carcinoma in situ; E-CD, E-cadherin; ER, estrogen receptor; IDC, invasive ductal carcinoma, IDH, intraductal hyperplasia; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; LN, lymph node; PgR, progesterone receptor.